+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Drug Device Combination Products Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4987030
  • Report
  • February 2020
  • Region: Global
  • 120 pages
  • Mordor Intelligence
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Abbott Laboratories
  • Allergen, Inc.
  • Boston Scientific Corp
  • CareFusion Corporation
  • GlaxoSmithKline plc
  • Medtronic Plc
  • MORE
The market is primarily driven by the growing prevalence of chronic diseases such as diabetes, respiratory diseases and cancer. Furthermore, the growing geriatric population and technological advances in drug delivery systems is projected to boost market growth over the forecast period. Moreover, expanding applications of drug device combination products, new developments over the period are expected to bolster the market growth.

However, stringent regulatory policies, product recalls and complications associated with some of the drug device combinations are expected to hamper the market. On the other hand, growing healthcare infrastructure, advances in drug delivery technologies are expected to aid the market growth over the period.

Key Market Trends

Transdermal Patches are Expected to Grow at Notable Rates
  • Transdermal patches are the medicated adhesive patch that is placed on the skin to deliver a specific dose of the drug. Transdermal patches are used in many applications such as pain relief, neurological and others.
  • Drug-eluting stents segment of the market is projected to have a significant growth rate owing to growing cardiovascular diseases coupled with the ageing population. Moreover, the development of new products and recent product launches are expected to boost the segment share.
  • According to the World Health Organization, cardiovascular diseases cause 17.9 million deaths each year. According to the International Diabetes Federation (IDF), in 2017, about 425 million people worldwide were living with diabetes.
  • The increasing adaptation of prefilled insulin pens coupled with the advent of innovative drug combination products expected to boost the market growth over the forecast period.
North America is Projected to Have Significant Market Share

North America is projected to have a significant market share among the regions owing to the adaptation of drug-device combination products coupled with well-established healthcare infrastructure in the region. In addition, new product launches, high R&D investments and the growing prevalence of chronic diseases is expected to boost the regional growth. Moreover, Due to the rising incidence of diseases such as diabetes, neurological pain and cancer in emerging countries of Asia-Pacific are expected to boost the Asia Pacific regional share. Furthermore, companies’ interest in expanding into developing economies of Asia coupled with the presence of a large pool of diseased population expected to fuel Asia Pacific market growth rate.

Competitive Landscape

The drug device combination market is moderately fragmented with many market players. Market players focusing on new product developments, collaborations and regional expansion to expand their market share.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • Report customization as per the client's requirements.
  • 3 months of analyst support.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abbott Laboratories
  • Allergen, Inc.
  • Boston Scientific Corp
  • CareFusion Corporation
  • GlaxoSmithKline plc
  • Medtronic Plc
  • MORE
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Incidence of Chronic Diseases coupled with Need For Novel Drug Delivery Systems
4.2.2 Increase in Geriatric Population
4.3 Market Restraints
4.3.1 Stringent Government Policies
4.3.2 Product Recalls and Associated Complications
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

5.1 By Products
5.1.1 Drug Eluting Stents
5.1.2 Transdermal Patches
5.1.3 Infusion Pumps
5.1.4 Drug Eluting Balloon
5.1.5 Others
5.2 By Application
5.2.1 Cardiovascular
5.2.2 Diabetes
5.2.3 Cancer Treatment
5.2.4 Others
5.3 By End-User
5.3.1 Hospitals
5.3.2 Ambulatory Surgical Centers
5.3.3 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Medtronic Plc
6.1.3 Boston Scientific Corp
6.1.4 Becton, Dickinson and Company
6.1.5 Novartis AG
6.1.6 GlaxoSmithKline plc
6.1.7 Allergen, Inc.
6.1.8 W. L. Gore & Associates, Inc.
6.1.9 Stryker Corporation
6.1.10 CareFusion Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Abbott Laboratories
  • Medtronic Plc
  • Boston Scientific Corp
  • Becton, Dickinson and Company
  • Novartis AG
  • GlaxoSmithKline plc
  • Allergen, Inc.
  • W. L. Gore & Associates, Inc.
  • Stryker Corporation
  • CareFusion Corporation
Note: Product cover images may vary from those shown
Adroll
adroll